세계의 비스테로이드성 항염증제 시장 : 인사이트, 경쟁 구도 및 시장 예측(2030년)

Non-Steroidal Anti-Inflammatory Drugs Market By Indication (Arthritis, Migraine, Ophthalmic Diseases, And Others), By Route Of Administration (Oral And Parenteral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, And E-Commerce), and by geography is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of chronic pain and inflammation such as migraine, arthritis, ophthalmic diseases, and others and the increasing research & developmental activities concerning to the non-steroidal anti-inflammatory drugs across the globe

The global non-steroidal anti-inflammatory drugs market is estimated to grow at a CAGR of 5.67% during the forecast period from 2024 to 2030. The non-steroidal anti-inflammatory drugs market is observing substantial market growth due to the growing burden of chronic pain and inflammation diseases such as arthritis, migraine, and others. Further, the increasing geriatric population base prone to chronic pain and inflammation & related diseases and the rising preference for NSAIDs over other classes of pain relievers owing to the fewer side effects offered by the class will aid in surging the demand for non-steroidal anti-inflammatory drugs. Additionally, increasing drug approvals and launches, increasing research and development activities on non-steroidal anti-inflammatory drugs, for instance, research on selective cyclooxygenase-2 (COX-2) inhibitors for pain management and other such research will increase the demand for nonsteroidal anti-inflammatory drugs in the market. Therefore, the market for non-steroidal anti-inflammatory drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.

Non-Steroidal Anti-Inflammatory Drugs Market Dynamics:

One of the key aspects driving the non-steroidal anti-inflammatory drugs market is the rising burden of chronic pain and inflammation across the globe.

According to the Centre for Disease Control and Prevention (CDC) 2020, in 2019, 20.4% of adults had chronic pain and about 7.4% of adults had high-impact chronic pain that frequently limited life or work activities in the past 3 months in the United States. Chronic pain and high-impact chronic pain both increase with age and were highest among adults aged 65 and over, in the United States. Moreover, as per the same source, non-Hispanic white adults (23.6%) were more likely to have chronic pain compared with non-Hispanic black (19.3%), Hispanic (13.0%), and non-Hispanic Asian (6.8%) adults, in 2019.

Also, NSAIDs are the most commonly prescribed drugs for the treatment of mild to severe pain. The American Academy of Family Physicians recommends the use of ibuprofen and naproxen as the first line of treatment for mild to moderate pain. Thus, such positive recommendations are expected to boost the NSAIDs market growth during the forecast period from 2022 - 2028.

Moreover, the increasing research on selective cyclooxygenase-2 (COX-2) inhibitors is one of the important market trends. Current NSAIDs, such as diclofenac and ibuprofen, not only inhibit COX-2 activity but also COX-1 activity, resulting in undesirable side effects. Selective COX-2 inhibitors continue to be a difficult and ambiguous area for pharmaceutical companies. Celebrex, manufactured by Pfizer, is currently the only COX-2 inhibitor commercially available in the United States. However, many pharmaceutical behemoths are now investing heavily in the development of new COX-2 inhibitors for the treatment of pain and inflammation. For instance, Crystal Genomics is running a phase 3 clinical trial for CG100649, a dual COX-2 and carbonic anhydrase (CA) inhibitor for the treatment of osteoarthritis.

Lastly, the increasing number of NSAID launches and approvals in the market will aid in increasing its demand in the upcoming years. For instance, in May 2022, Heron Therapeutics, Inc. announced that the US Food and Drug Administration (FDA) approved Zynrelef, an extended-release dual-acting local anesthetic of bupivacaine and meloxicam for pain management.

Therefore, the factors stated above collectively will drive the overall non-steroidal anti-inflammatory drugs market throughout the forecast period from 2024-2030.

However, the high cost of drug development and launches, side effects associated with NSAIDs, and the stringent regulatory approval process may prove to be challenging factors for the non-steroidal anti-inflammatory drugs market growth.

The non-steroidal anti-inflammatory drugs market was moderately impacted during the period of COVID- 19 pandemic. During the initial stage of the pandemic, the sale of NSAIDs suffered a downfall owing to the imposition of strict lockdown rules, and disruption in manufacturing, and supply. Also, owing to the strict lockdown rules many elective surgeries and diagnosis sessions were postponed, impacting the demand for NSAIDs. However, the government classified medicines and drugs under emergency products during the pandemic, thereby leading to an increase in their demand or sales. Moreover, with the involvement of online pharmacies, the sale of many over-the-counter medicines increased, impacting the market of non-steroidal anti-inflammatory drugs. Additionally, with the ease of lockdown restrictions, the upturn of resources and supply chain, the administration of the vaccine to the public, and the increasing number of surgeries and diagnoses of chronic pain and inflammation-related diseases, the demand for non-steroidal anti-inflammatory drugs increases, and is expected to do the same during the forecast period from 2022 - 2028.

Non-Steroidal Anti-Inflammatory Drugs Market Segment Analysis:

Non-Steroidal Anti-Inflammatory Drugs Market by Indication (Arthritis, Migraine, Ophthalmic Diseases, and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and E-Commerce), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the Indication segment of the non-steroidal anti-inflammatory drugs market, the arthritis segment is expected to have a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of arthritis across the globe. Also, the expanding launches and strategic investments, and other activities by the key players related to the segment will support driving its market during the forecast period.

For instance, as per the Global RA Network 2022, more than 350 million people had arthritis, in 2022, globally. Further, the World Health Organization (WHO), 2022, more than 14 million people had rheumatoid arthritis (RA), in 2022, across the globe.

Thus, the rising prevalence of the different types of arthritis is quite high across the globe, ultimately leading to the increased demand for arthritis-managing NSAIDs.

Moreover, the presence of huge arthritis-treating NSAIDs in the pipeline is expected to enter the market during the forecast period creating a positive outlook for the market. For instance, Overseas Pharmaceuticals, Ltd., is conducting a Phase III efficacy study with the title 'A randomized, double-blind, parallel-arm study comparing the efficacy of investigational product "Ibuprofen Modified-Release Tablets 800 mg" and placebo in patients with chronic pain related to osteoarthritis of the knee.' The primary objective is to determine the analgesic efficacy of orally administered IBUMR in patients with osteoarthritis (OA) of the knee. Thus, such research and development activities will increase the chance of the availability of the various drug in the market as the demand for NSAIDs in the treatment of arthritis is rising.

Further, various other strategic steps by the key players in the market will help in increasing demand for NSAIDs. For instance, in January 2022, the U.S. Food and Drug Administration approved a generic version of Pfizer's Celebrex (celecoxib), an oral medication used to treat inflammation and pain caused by ankylosing spondylitis and other disorders. The generic drug is also indicated to treat osteoarthritis, rheumatoid arthritis, juvenile arthritis, acute pain, and primary dysmenorrhea.

Therefore, owing to the above-mentioned factors, the demand for arthritis drugs upsurges, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the global non-steroidal anti-inflammatory drugs market during the forecast period.

North America is expected to dominate the overall Non-Steroidal Anti-Inflammatory Drugs Market:

Among all the regions, North America is expected to dominate the global non-steroidal anti-inflammatory drugs market during the forecast period from 2024-2030.

This can be ascribed to the increasing demand for non-steroidal anti-inflammatory drugs in the region owing to increasing chronic pain and rising adoption of NSAIDs in the management of headaches, migraine, toothaches, menstrual pain, and others. Further, the rising preference for NSAIDs over other classes of pain relievers, and the presence of key domicile players in the region, among others are the key factors that contribute to the growth of the non-steroidal anti-inflammatory drugs market in North America during the forecast period from 2022 - 2028.

For instance, as per the study conducted by the Centre for Disease Control and Prevention (CDC) 2022, it was stated that in 2020, about one in four US adults, or about 58.5 million people were diagnosed with arthritis. By the year 2040, an estimated 78.4 million US adults aged 18 years and older will be diagnosed with arthritis.

The data provided by the Arthritis Society Canada, 2022, stated that in 2022, nearly 6 million people were living with arthritis in Canada. The number is expected to rise to 9 million in 2040.

Additionally, as per the Migraine Research Foundation (2023), migraine is a highly prevalent neurological disease, affecting nearly 40 million men, women, and children in the U.S. While most sufferers experience attacks once or twice a month, more than 4 million people have chronic daily migraine, with at least 15 migraine days per month.

Thus, the rising prevalence of chronic pain and inflammation-related disorders such as migraine, arthritis, and others will propel the demand for non-steroidal anti-inflammatory drugs during the forecast period.

Furthermore, the increasing activities by the key players in the region will in turn increase the demand for the product during the forecast period. For instance, in September 2020, Dr. Reddy launched the diclofenac sodium topical gel 1% as an OTC drug for arthritis pain in the United States. Also, in August 2022, Dr. Reddy's Laboratories Ltd, announced the re-launch of over-the-counter (OTC) Naproxen Sodium Tablets USP, 220 mg, in the US market, as approved by the US Food and Drug Administration (USFDA).

Moreover, the market players in the country are continuously focusing on the development of novel drugs to tackle these indications using NSAIDs, and they are also adopting various strategies to develop better drugs with reduced side effects. For instance, in February 2020, the FDA approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1%) for the temporary relief of arthritis pain.

Therefore, the interplay of the aforementioned factors above would provide a conducive growth environment for the North American non-steroidal anti-inflammatory drugs market.

Non-Steroidal Anti-Inflammatory Drugs Market Key Players:

Some of the key market players operating in the non-steroidal anti-inflammatory drugs market include Pfizer Inc., Johnson & Johnson Services, Inc., Bayer AG, Sanofi, GSK plc., Heron Therapeutics, Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group PLC., Assertio Holdings, Inc., AstraZeneca, Boehringer Ingelheim Ltd., Assertio Holdings, Inc., Horizon Therapeutics plc, Perrigo Company plc, Viatris Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Eli Lilly and Company, among others.

Recent Developmental Activities in the Non-Steroidal Anti-Inflammatory Drugs Market:

In August 2022, Strides Pharma Global Pte Ltd received approval from the US health regulator for generic naproxen sodium soft gel capsules, used to treat pain or inflammation.

In August 2022, Alkem Labs announced the launch of Ibuprofen and Famotidine tablets in the U.S. after receiving approval from the U.S. FDA.

In February of 2022, Strides Pharma Science Limited received approval for Ibuprofen Oral Suspension from the United States Food & Drug Administration (USFDA).

Key Takeaways from the Non-Steroidal Anti-Inflammatory Drugs Market Report Study

• Market size analysis for current non-steroidal anti-inflammatory drugs market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the non-steroidal anti-inflammatory drugs market.
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global non-steroidal anti-inflammatory drugs market.
• Various opportunities available for the other competitor in the non-steroidal anti-inflammatory drugs market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030.
• Which are the top-performing regions and countries in the current non-steroidal anti-inflammatory drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for non-steroidal anti-inflammatory drugs market growth in the coming future?

Target Audience who can be benefited from this Non-Steroidal Anti-Inflammatory Drugs Market Report Study

• Non-steroidal anti-inflammatory drugs providers
• Research organizations and consulting companies
• Non-steroidal anti-inflammatory drugs -related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in non-steroidal anti-inflammatory drugs
• Various manufacturers want to know more about the non-steroidal anti-inflammatory drugs market and the latest developments in the non-steroidal anti-inflammatory drugs market.

Frequently Asked Questions for the Non-Steroidal Anti-Inflammatory Drugs Market:

1. What are non-steroidal anti-inflammatory drugs?

The non-steroidal anti-inflammatory drugs (NSAIDs) refer to a group a drug class that reduces pain, decreases fever, prevents blood clots, and decreases inflammation in higher doses. NSAIDs block enzymes in the body that produces prostaglandins. Prostaglandins are a group of naturally occurring fatty acids that play a role in pain and inflammation.

2. What is the global market for non-steroidal anti-inflammatory drugs?

The global non-steroidal anti-inflammatory drugs market is estimated to grow at a CAGR of 5.67% during the forecast period from 2024 to 2030.

3. What are the drivers for the global non-steroidal anti-inflammatory drugs market?

The non-steroidal anti-inflammatory drugs market is witnessing positive market growth owing to the factors such as the growing burden of chronic pain and inflammation causing diseases such as arthritis, migraine, and others, the increasing geriatric population base prone to chronic pain, rising preference for NSAIDs over other class of pain relievers, increasing research on selective cyclooxygenase-2 (COX-2) inhibitors, increasing new drug launches and approvals, presence of key players in the market, and others will create an exigency for the non-steroidal anti-inflammatory drugs market.

4. Who are the key players operating in the global non-steroidal anti-inflammatory drugs market?

Some of the key market players operating in the non-steroidal anti-inflammatory drugs market include Pfizer Inc., Johnson & Johnson Services, Inc., Bayer AG, Sanofi, GSK plc., Heron Therapeutics, Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group PLC., Assertio Holdings, Inc., AstraZeneca, Boehringer Ingelheim Ltd., Assertio Holdings, Inc., Horizon Therapeutics plc, Perrigo Company plc, Viatris Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Eli Lilly and Company, among others.

5. Which region has the highest share of the non-steroidal anti-inflammatory drugs market?

Among all the regions, North America is estimated to hold a significant revenue share in the global non-steroidal anti-inflammatory drugs market. This can be ascribed to the increasing demand for non-steroidal anti-inflammatory drugs among the patients in the region owing to increasing chronic pain and rising adoption of NSAIDs in headaches, migraine, toothaches, menstrual pain, and others. Further, the rising preference for NSAIDs over other classes of pain relievers, and the presence of key domicile players in the region are the reasons which act as a supportive factor for the North America non-steroidal anti-inflammatory drugs market growth.

Table of Contents

1.Non-Steroidal Anti-Inflammatory Drugs Market Report Introduction

2.Non-Steroidal Anti-Inflammatory Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

4. Non-Steroidal Anti-Inflammatory Drugs Market Key Factors Analysis

• 4.1. Non-Steroidal Anti-Inflammatory Drugs Market Drivers
  • 4.1.1. The growing burden of chronic pain and inflammation
  • 4.1.2. Increasing geriatric population base prone to chronic pain
  • 4.1.3. Rising preference for NSAIDs over other classes of pain relievers
  • 4.1.4. Increasing research on selective cyclooxygenase-2 (COX-2) inhibitors
• 4.2. Non-Steroidal Anti-Inflammatory Drugs Market Restraints and Challenges
  • 4.2.1. High cost of drug development and launches
  • 4.2.2. Side effects associated with NSAIDs
  • 4.2.3. A stringent regulatory approval process
• 4.3. Non-Steroidal Anti-Inflammatory Drugs Market Opportunities
  • 4.3.1. Availability of a robust product portfolio of NSAIDs in various emerging countries
  • 4.3.2. Increasing investments in R&D activities of non-steroidal anti-inflammatory drugs

5. Non-Steroidal Anti-Inflammatory Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Non-Steroidal Anti-Inflammatory Drugs Market

7. Non-Steroidal Anti-Inflammatory Drugs Market Layout

• 7.1. By Indication
  • 7.1.1. Arthritis
  • 7.1.2. Migraine
  • 7.1.3. Ophthalmic Diseases
  • 7.1.4. Others
• 7.2. By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
• 7.3. By Distribution Channel
  • 7.3.1. Hospital Pharmacy
  • 7.3.2. Retail Pharmacy
  • 7.3.3. E-commerce
• 7.4. By Geography
  • 7.4.1. North America
    • 7.4.1.1. United States Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.1.2. Canada Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.1.3. Mexico Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
  • 7.4.2. Europe
    • 7.4.2.1. France Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.2.2. Germany Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.2.3. United Kingdom Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.2.4. Italy Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.2.5. Spain Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.2.6. Rest of Europe Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
  • 7.4.3. Asia-Pacific
    • 7.4.3.1. China Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.3.2. Japan Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.3.3. India Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.3.4. Australia Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.3.5. South Korea Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.3.6. Rest of Asia Pacific Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
  • 7.4.4. Rest of the World (RoW)
    • 7.4.4.1. Middle East Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.4.2. Africa Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)
    • 7.4.4.3. South America Non-Steroidal Anti-Inflammatory Drugs Market in USD million (2021-2030)

8. Non-Steroidal Anti-Inflammatory Drugs Market Company and Product Profiles

• 8.1. Pfizer Inc.
  • 8.1.1. Company Overview
  • 8.1.2. Company Snapshot
  • 8.1.3. Financial Overview
  • 8.1.4. Product Listing
  • 8.1.5. Entropy
• 8.2. Johnson & Johnson Services, Inc.
  • 8.2.1. Company Overview
  • 8.2.2. Company Snapshot
  • 8.2.3. Financial Overview
  • 8.2.4. Product Listing
  • 8.2.5. Entropy
• 8.3. Bayer AG
  • 8.3.1. Company Overview
  • 8.3.2. Company Snapshot
  • 8.3.3. Financial Overview
  • 8.3.4. Product Listing
  • 8.3.5. Entropy
• 8.4. Sanofi
  • 8.4.1. Company Overview
  • 8.4.2. Company Snapshot
  • 8.4.3. Financial Overview
  • 8.4.4. Product Listing
  • 8.4.5. Entropy
• 8.5. GSK plc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Snapshot
  • 8.5.3. Financial Overview
  • 8.5.4. Product Listing
  • 8.5.5. Entropy
• 8.6. Heron Therapeutics, Inc.
  • 8.6.1. Company Overview
  • 8.6.2. Company Snapshot
  • 8.6.3. Financial Overview
  • 8.6.4. Product Listing
  • 8.6.5. Entropy
• 8.7. Strides Pharma Science Limited
  • 8.7.1. Company Overview
  • 8.7.2. Company Snapshot
  • 8.7.3. Financial Overview
  • 8.7.4. Product Listing
  • 8.7.5. Entropy
• 8.8. Sun Pharmaceutical Industries Ltd.
  • 8.8.1. Company Overview
  • 8.8.2. Company Snapshot
  • 8.8.3. Financial Overview
  • 8.8.4. Product Listing
  • 8.8.5. Entropy
• 8.9. Reckitt Benckiser Group PLC.
  • 8.9.1. Company Overview
  • 8.9.2. Company Snapshot
  • 8.9.3. Financial Overview
  • 8.9.4. Product Listing
  • 8.9.5. Entropy
• 8.10. Assertio Holdings, Inc.
  • 8.10.1. Company Overview
  • 8.10.2. Company Snapshot
  • 8.10.3. Financial Overview
  • 8.10.4. Product Listing
  • 8.10.5. Entropy
• 8.11. AstraZeneca
  • 8.11.1. Company Overview
  • 8.11.2. Company Snapshot
  • 8.11.3. Financial Overview
  • 8.11.4. Product Listing
  • 8.11.5. Entropy
• 8.12. Boehringer Ingelheim Ltd.
  • 8.12.1. Company Overview
  • 8.12.2. Company Snapshot
  • 8.12.3. Financial Overview
  • 8.12.4. Product Listing
  • 8.12.5. Entropy
• 8.13. Assertio Holdings, Inc.
  • 8.13.1. Company Overview
  • 8.13.2. Company Snapshot
  • 8.13.3. Financial Overview
  • 8.13.4. Product Listing
  • 8.13.5. Entropy
• 8.14. Horizon Therapeutics plc
  • 8.14.1. Company Overview
  • 8.14.2. Company Snapshot
  • 8.14.3. Financial Overview
  • 8.14.4. Product Listing
  • 8.14.5. Entropy
• 8.15. Perrigo Company plc
  • 8.15.1. Company Overview
  • 8.15.2. Company Snapshot
  • 8.15.3. Financial Overview
  • 8.15.4. Product Listing
  • 8.15.5. Entropy
• 8.16. Viatris Inc.
  • 8.16.1. Company Overview
  • 8.16.2. Company Snapshot
  • 8.16.3. Financial Overview
  • 8.16.4. Product Listing
  • 8.16.5. Entropy
• 8.17. Dr. Reddy's Laboratories Ltd.
  • 8.17.1. Company Overview
  • 8.17.2. Company Snapshot
  • 8.17.3. Financial Overview
  • 8.17.4. Product Listing
  • 8.17.5. Entropy
• 8.18. Teva Pharmaceutical Industries Ltd.
  • 8.18.1. Company Overview
  • 8.18.2. Company Snapshot
  • 8.18.3. Financial Overview
  • 8.18.4. Product Listing
  • 8.18.5. Entropy
• 8.19. Merck & Co., Inc.
  • 8.19.1. Company Overview
  • 8.19.2. Company Snapshot
  • 8.19.3. Financial Overview
  • 8.19.4. Product Listing
  • 8.19.5. Entropy
• 8.20. Eli Lilly and Company
  • 8.20.1. Company Overview
  • 8.20.2. Company Snapshot
  • 8.20.3. Financial Overview
  • 8.20.4. Product Listing
  • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us